Medicine
Firazyr 30 mg/3 mL injection
Firazyr 30 mg/3 mL injection is a prescription medicine containing Icatibant for subcutaneous use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store between 2 - 25° C (36 - 77° F). Store in carton until…
Key facts
- Active ingredient (INN)
- Icatibant
- Brand
- Firazyr
- Strength
- 30 mg/3 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 3 mL, 3 syringes of 3 mL
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store between 2 - 25° C (36 - 77° F). Store in carton until time of administration.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B06AC02 Icatibant
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 August 2011
- Identifiers
- RxCUI 1148141, 1148145DailyMed set ID ed6657ca-ab68-477a-9968-e12dc928b540NDC 54092-702Application NDA022150
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 3 mL in 1 syringe, glass | 54092-702-01 | Takeda Pharmaceuticals | 25 August 2011 |
| 1 syringe, glass in 1 carton / 3 mL in 1 syringe, glass | 54092-702-02 | Takeda Pharmaceuticals | 25 August 2011 |
| 3 syringe, glass in 1 carton / 3 mL in 1 syringe, glass | 54092-702-03 | Takeda Pharmaceuticals | 25 August 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Icatibant 30 mg/3 mL injection.
Clinical summary
Icatibant is a bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. It is available as injection for subcutaneous use. MedsAcross supplies Icatibant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IcatibantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Firazyr prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Firazyr: European public assessment report (EPAR) · European Medicines Agency
- Icatibant Accord: European public assessment report (EPAR) · European Medicines Agency
Need Firazyr 30 mg/3 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.